FindTrial
Sign In

Icotinib concurrent thoracic radiotherapy treat for advanced non-small-cell lung cancer (NSCLC) with an activating EGFR gene mutation

Icotinib concurrent thoracic radiotherapy treat for advanced non-small-cell lung cancer (NSCLC) with an activating EGFR gene mutation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16010262
Enrollment
Unknown
Registered
2016-12-27
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced lung adenocarcinoma

Interventions

icotinib plus concurrent thoracic radiotherapy group:radiotherapy
icotinib plus concurrent thoracic radiotherapy group:icotinib
icotinib therapy group:icotinib

Sponsors

Shaoxing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with stage IV non-small cell lung cancer harboring activating EGFR mutation which confirmed by histopathological or cytological examination; have at least one measurable lesion; with lesions larger than 20 mm detected by CT or MRI, or larger than 10 mm detected by PET-CT; could survival more than 3 months.

Exclusion criteria

Exclusion criteria: Have history of primary lung cancer irradiation; with uncontrolled severe acute infection; have serious heart diseases; have mental diseases, nerve diseases or mental disorders that are hard to control.

Design outcomes

Primary

MeasureTime frame
PFS;—

Secondary

MeasureTime frame
ORR;DCR;adverse events;OS;—

Countries

China

Contacts

Public ContactWang Jianfang

Shaoxing People's Hospital

sxwxdd@163.com+86 13065582209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026